Maravai LifeSciences (MRVI) Q4 2025 earnings summary

Executive summary

• Full-year 2025 revenue was $185.7 million, with Q4 revenue of $49.9 million and a return to positive adjusted EBITDA of $0.5 million after several loss quarters.

• Cost savings exceeded $65 million annualized, well above the initial $50 million target, supporting margin expansion and profitability.

• TriLink and Cygnus segments were renamed for brand alignment, with TriLink driving growth in GMP consumables and CDMO, and Cygnus growth led by core customers.

• Organizational restructuring and cost reduction initiatives were completed ahead of schedule, positioning for operational excellence and improved profitability.

Financial highlights

• Q4 revenue: $49.9 million, with 18% year-over-year growth excluding $14.3 million COVID CleanCap comp; full-year revenue: $185.7 million.

• Q4 GAAP net loss: $63 million (includes $25.8 million intangible asset impairment and $12.1 million restructuring charges); full-year GAAP net loss: $230.8 million.

• Adjusted EBITDA Q4: $0.5 million (vs. -$1.1 million Q4 2024); full-year adjusted EBITDA: -$31.2 million.

• Ended year with $216.9 million cash, $294.2 million long-term debt; net cash of $(77.3) million.

• Q4 adjusted EPS loss: $0.04; full-year adjusted EPS loss: $0.29.

Outlook and guidance

• 2026 revenue expected at $200–$210 million (8–13% growth); TriLink to grow low double digits, Cygnus low to mid single digits.

• Full-year adjusted EBITDA guidance: $18–$20 million, a $50–$52 million improvement over 2025.

• Gross margin expansion of ~1,200 basis points expected, driven by cost actions and product mix.

• Operating expenses to decline ~13%; G&A down 18%, sales/marketing down 13%, R&D modestly up.

• Net capital expenditures for 2026 expected at $4–$6 million.